Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001380003 | SCV001577923 | likely pathogenic | Developmental and epileptic encephalopathy, 8 | 2020-09-03 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exon(s) 2-8 of the ARHGEF9 gene. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product. This variant has been observed in individual(s) with clinical features of ARHGEF9-related conditions (Invitae). This variant disrupts the p.Arg338 amino acid residue in ARHGEF9. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 26834553, Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |